PKM and lung cancer: Shi et al. reported that knockdown of pyruvate kinase M2 (PKM2), the final rate-limiting enzyme of the glycolytic pathway, caused the accumulation of docetaxel in lung cancer cells and synergistically strengthened the efficiency of chemotherapy in mice [31].